June 27 (Reuters) -

Alumis set the pricing of its U.S. initial public

offering at $16 per share, the lower end of its price range,

valuing it at around $902 million.

Previously known as Esker Therapeutics, Alumis is moving

ahead with its listing more than three months after it secured

an upsized $259 million Series C financing. It aims to raise

around $210 million, the company, involved in developing oral

therapies to address immune dysfunction said late on Thursday.

Alumis expects to list on the Nasdaq under the symbol

"ALMS". Morgan Stanley, Leerink Partners, Cantor Fitzgerald and

Guggenheim Securities are the underwriters for the offering.